Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response

• Published in: International journal of radiation oncology, biology, physics Vol. 110; no. 1; pp. 237 - 248
• Main Authors: Wang, Kyle, Mavroidis, Panayiotis, Royce, Trevor J., Falchook, Aaron D., Collins, Sean P., Sapareto, Stephen, Sheets, Nathan C., Fuller, Donald B., El Naqa, Issam, Yorke, Ellen, Grimm, Jimm, Jackson, Andrew, Chen, Ronald C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-05-2021
• Subjects: BIOLOGICAL RADIATION EFFECTS; Humans; Male; Models, Biological; Models, Theoretical; NEOPLASMS; Organs at Risk - radiation effects; Patient Reported Outcome Measures; Penis - radiation effects; PROSTATE; Prostatic Neoplasms - pathology; Prostatic Neoplasms - radiotherapy; QUALITY OF LIFE; Radiation Dose Hypofractionation; RADIATION DOSES; RADIOLOGY AND NUCLEAR MEDICINE; Radiosurgery - adverse effects; RADIOTHERAPY; Rectum - radiation effects; REVIEWS; TOXICITY; Urethra - radiation effects; Urinary Bladder - radiation effects
• ISSN: 0360-3016; 1879-355X
• DOI: 10.1016/j.ijrobp.2020.09.054

Ultrahypofractionationed radiation therapy for prostate cancer is increasingly studied and adopted. The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiotherapy therefore aimed to review studies examining toxicity and quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer and model its effect.
We performed a systematic PubMed search of prostate SBRT studies published between 2001 and 2018. Those that analyzed factors associated with late urinary, bowel, or sexual toxicity and/or quality of life were included and reviewed. Normal tissue complication probability modelling was performed on studies that contained detailed dose/volume and outcome data.
We found 13 studies that examined urinary effects, 6 that examined bowel effects, and 4 that examined sexual effects. Most studies included patients with low-intermediate risk prostate cancer treated to 35-40 Gy. Most patients were treated with 5 fractions, with several centers using 4 fractions. Endpoints were heterogeneous and included both physician-scored toxicity and patient-reported quality of life. Most toxicities were mild-moderate (eg, grade 1-2) with a very low overall incidence of severe toxicity (eg, grade 3 or higher, usually <3%). Side effects were associated with both dosimetric and non-dosimetric factors.
Prostate SBRT appears to be overall well tolerated, with determinants of toxicity that include dosimetric factors and patient factors. Suggested dose constraints include bladder V(Rx Dose)Gy <5-10 cc, urethra Dmax <38-42 Gy, and rectum Dmax <35-38 Gy, though current data do not offer firm guidance on tolerance doses. Several areas for future research are suggested.